

## COPD11 PROGRAMME - WEDNESDAY 20 JUNE 2018

07:30	Registration	
8.30 – 10.30am	<p><b>WORKSHOPS:</b></p> <p><b>W1: Driving up spirometry and lung function standards</b>  <i>Chair: Prof Brendan Cooper and Dr Rachel Jordan</i>  <b>Quality Assured Spirometry</b></p> <ul style="list-style-type: none"> <li>UK primary care spirometry experience  <b>Prof Mike Morgan (UK)</b></li> <li>ERS European Spirometry Driving Licence  <b>Prof Brendan Cooper (UK)</b></li> <li>Discussion</li> </ul> <p><b>Interpreting the Test</b></p> <ul style="list-style-type: none"> <li>Interpreting Spirometry in the Community  <b>Prof Felip Burgos (Spain)</b></li> <li>Detecting pre-COPD - <b>Dr James Stockley (UK)</b></li> <li>Discussion</li> </ul> <p><b>W2: Scientific advances in exacerbations</b>  <i>Chair: Prof Rob Stockley</i></p> <ul style="list-style-type: none"> <li>Microbiome- interesting or useful?  <b>Prof Wisia Wedzicha (UK)</b></li> <li>A new definition - <b>Prof Alvar Agusti (Spain)</b></li> <li>PMN function - <b>Dr Elizabeth Sapey (UK)</b></li> <li>Oxidants - <b>Prof Ian Adcock (UK)</b></li> <li>Eosinophils – the cause or association  <b>Prof Chris Brightling (UK)</b></li> </ul>	<p>08.30-9.30am</p> <p><b>Industry session – Workshop</b>  <b>The evolving treatment paradigm for COPD</b></p> <ul style="list-style-type: none"> <li>Chair’s Introduction  <b>Dr Elizabeth Sapey (UK)</b></li> <li>Towards precision medicine in COPD  <b>Prof Paul Jones (UK)</b></li> <li>What is the emerging evidence and what are the clinical implications?  <b>Dr Emma Hilton (UK)</b></li> </ul> <p>09.30-10.30am</p> <p><b>Industry session – Workshop</b>  <b>The Inhaled Corticosteroid Controversy</b>  <b>Prof Dave Singh (UK)</b></p> <ul style="list-style-type: none"> <li>The evidence for the use of Inhaled Corticosteroids</li> <li>Personalised medicine – Optimal use of Inhaled Corticosteroids</li> <li>Inhaled COPD therapies in the real world</li> </ul>
10.30-11.00am	<b>REFRESHMENT BREAK</b>	
11.00–1.00pm	<p><b>OPENING PLENARY SESSION - PS1: Early Origins of COPD</b>  <i>Chair: Prof Rob Stockley</i></p> <ul style="list-style-type: none"> <li>Role of early life</li> <li>What is the mechanism of fetal programming?</li> <li>Identify &amp; manage individuals at risk</li> <li>Implementing intervention (but I feel well)</li> <li>Discussion</li> <li>Young investigator presentation</li> <li>Lifetime achievement presentation</li> </ul> <p style="text-align: right;"> <b>Prof Sonia Buist (USA)</b>  <b>Prof Cindy McEvoy (USA)</b>  <b>Prof Peter Sly (Australia)</b>  <b>Prof David Halpin (UK)</b> </p>	
1.00-2.00pm	<b>LUNCH BREAK</b>	
2.00-3.30pm	<p><b>CS1: Treatment paradigms</b>  <i>Chair: Prof Leo Fabbri and Prof Peter Sly</i></p> <ul style="list-style-type: none"> <li>Eosinophils – real or artefact?  <b>Dr Richard Russell (UK)</b></li> <li>BCOS - <b>Dr Anthony de Soyza (UK)</b></li> <li>Reversibility testing – is it time to revisit and think differently? - <b>Dr Marc Miravittles (Spain)</b></li> <li>Are bronchodilators additive in an individual rather than group data - <b>Prof Dave Singh (UK)</b></li> <li>Discussion</li> </ul>	<p><b>BS1: Science and Big Data</b>  <i>Chair: Dr Alice Turner and Prof Gary Anderson</i></p> <ul style="list-style-type: none"> <li>Health care informatics – challenges and limitation - <b>Dr Jennifer Quint (UK)</b></li> <li>COPD Gene – <b>Dr Brian Hobbs (USA)</b></li> <li>Understanding associations (by chance, cause, effect) - models - <b>Prof Rob Stockley (UK)</b></li> <li>Big data and genomics / epigenetics  <b>Dr Dawn DeMeo (USA)</b></li> <li>Discussion</li> </ul>
3.30-4.00pm	<b>REFRESHMENT BREAK</b>	
4.00-6.00pm	<p><b>PLENARY SESSION - PS2: Managing COPD – Learning from global studies</b>  <i>Chair: Prof Bartolome Celli and Dr Jennifer Quint</i></p> <ul style="list-style-type: none"> <li>What have we learnt from big datasets (ECLIPSE, COPD gene, Big trials)  <b>Prof Peter Calverley (UK)</b></li> <li>How is this helping us manage the individual patient  <b>Prof Jorgen Vestbo (Denmark)</b></li> <li>What else do we need to do <ul style="list-style-type: none"> <li>Real world studies</li> <li>Clinical trial design: How many more?</li> </ul> </li> <li>Young investigator presentation  <b>Prof Dave Singh (UK)</b>  <b>Prof Nicolas Roche (France)</b>  <b>Dr Kevin Mortimer (UK)</b></li> </ul>	
6.00-8.00pm	<p>Poster viewing / Reception  Prize Award Ceremony</p>	

# COPD11 PROGRAMME - THURSDAY 21 JUNE 2018

7.30am	Registration	
8.00 – 10.00am	<p><b>WORKSHOPS:</b></p> <p><b>W3: Psychological &amp; behavioural aspects of COPD care</b>  <i>Chair: Prof Sally Singh and Dr Byron Thomashow</i></p> <ul style="list-style-type: none"> <li>Rehabilitation the poor treatment relation  <b>Prof Richard Casaburi (USA)</b></li> <li>Web based interventions  <b>Dr Emily Wan (USA)</b></li> <li>Psychology / palliative care  <b>Sharon Hudson (UK)</b></li> <li>Tim Griffiths memorial lecture  <b>Dr William Man (UK)</b></li> </ul> <p><b>W4: The science of new treatments</b>  <i>Chair: Prof Stephen Rennard</i></p> <ul style="list-style-type: none"> <li>Therapeutic discovery  <b>Prof Gary Anderson (Australia)</b></li> <li>Biologics  <b>Dr Donna Finch (UK)</b></li> <li>Other treatments in COPD – where are we going?  <b>Prof Peter Barnes (UK)</b></li> <li>Clinical trial development / outcomes (Phase II / III) – a new approach is needed  <b>Prof Peter Calverley (UK)</b></li> </ul>	<p>08.00-9.00am  <b>Industry session – Workshop</b></p> <p>09.00-10.00am  <b>Industry session – Workshop</b>  <b>Treatable traits in COPD</b>  <b>Prof Mona Bafadhel (UK)</b></p> <ul style="list-style-type: none"> <li>How do we use current understanding of pathophysiology guide COPD treatment</li> <li>The role of clinical and soluble biomarkers in current COPD treatment</li> <li>Precision medicine and future therapeutic interventions</li> </ul>
10.00-10.30am	<i>REFRESHMENT BREAK</i>	
10.30 – 12.30pm	<p><b>PLENARY SESSION - PS3: Personalising care</b>  <i>Chair: Prof Sonia Buist and Prof David Haplin</i></p> <ul style="list-style-type: none"> <li>Treatable traits  <b>Prof Alvar Agusti (Spain)</b></li> <li>Mismatch of subjective and objective measures - relationship to patient endotypes  <b>Prof Bartolome Celli (USA)</b></li> <li>GOLD 2017 algorithm after 1 year  <b>Prof Jorgen Vestbo (Denmark)</b></li> <li>Targeted therapy – POC assessment  <b>Dr John Hurst (UK)</b></li> <li>Young investigator presentation  <b>Dr Rosa Fanner (Spain)</b></li> <li>Lifetime achievement presentation</li> </ul>	
12.30-1.30pm	<i>LUNCH BREAK</i>	
1.30-3.00pm	<p><b>CS2: Advanced disease</b>  <i>Prof Mike Morgan and Dr Tobias Welte</i></p> <ul style="list-style-type: none"> <li>Readmissions - <b>Dr Jill Ohar (USA)</b></li> <li>Premature aging - <b>Dr Mauricio Rojas (USA)</b></li> <li>Lung volume reduction interventions for COPD  <b>Dr Nick Hopkinson (UK)</b></li> <li>NIV in advanced disease  <b>Prof Tobias Welte (Germany)</b></li> <li>Discussion</li> </ul>	<p><b>BS2: Immunity &amp; Inflammation</b>  <i>Chair: Dr Elizabeth Sapey and Prof Alvar Agusti</i></p> <ul style="list-style-type: none"> <li>Auto immunity / inflammation interface  <b>Prof Gary Anderson (Australia)</b></li> <li>Cancer inflammation immunity interface  <b>Dr Clara Green (UK)</b></li> <li>Bacterial colonisation / infection  <b>Prof Wisia Wedzicha (UK)</b></li> <li>Discussion</li> </ul>
3.00-3.30pm	<i>REFRESHMENT BREAK</i>	
3.30-5.00pm	<p><b>CLOSING PLENARY SESSION - PS4: Future visions</b>  <i>Chair: Prof Peter Barnes and Prof Gary Anderson</i></p> <ul style="list-style-type: none"> <li>Patient  <b>Dr Byron Thomashow (USA)</b></li> <li>Industry  <b>Prof Steve Rennard (USA)</b></li> <li>Healthcare system  <b>Prof Sue Hill OBE (UK)</b></li> <li>Genomics  <b>Dr Dawn DeMeo (USA)</b></li> <li>Biomarkers  <b>Prof Rob Stockley (UK)</b></li> <li>Discussion</li> </ul>	